CJC-1295 no DAC

CJC-1295 (no DAC) Nasal Spray is supplied by Crystal Peptides as a catalogued research material in the following format and strength: nasal spray, 10mg/10ml. This catalogue entry distinguishes the supplied formulation from other materials discussed in the GHRH analogue literature. The product designation does not establish formulation-specific biological activity or suitability for clinical use.

CJC-1295 without DAC is commonly used as a catalogue name for Modified GRF (1-29), a synthetic analogue of the biologically active 29-amino-acid region of human growth hormone-releasing hormone (GHRH). It incorporates four amino acid substitutions: D-Ala², Gln⁸, Ala¹⁵, and Leu²⁷. Unlike CJC-1295 with DAC, it lacks the Drug Affinity Complex associated with albumin binding. These names should therefore not be treated as interchangeable when evaluating published evidence.

Chemical properties and registry information

Research background and published evidence

Published research

The relevant literature encompasses GHRH peptide engineering, receptor pharmacology, and endocrine regulation. Published work on CJC-1295 includes studies of albumin-binding, DAC-containing analogues, which are distinct from Modified GRF (1-29). Such studies provide background on the GHRH analogue family but do not constitute direct evidence for this no-DAC nasal spray. Interpretation requires attention to the actual peptide structure, experimental model, formulation, and route reported in each publication.

Current scientific understanding

Modified GRF (1-29) is discussed in relation to GHRHR agonism and research into the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis. Relevant scientific questions include ligand–receptor interactions, downstream signalling, enzymatic degradation, and endocrine feedback. The absence of the DAC modification is a material structural distinction, not evidence of a particular exposure profile for the supplied spray. Compound-level pharmacology should be separated from experimentally established characteristics of a finished formulation.

Formulation note

Published research has predominantly examined other materials or routes rather than this nasal spray, 10mg/10ml. Findings from injected or differently formulated material cannot be transferred to this nasal spray formulation. In particular, the cited research background does not establish nasal absorption, bioavailability, stability, or biological responses for this product. Formulation-specific conclusions require direct analytical and experimental evidence concerning the finished material and its excipient composition.

Quality and testing

Refer to the batch-specific CoA for the analytical results associated with the supplied material. Review the batch identifier, sample description, methods, and reported findings to determine whether testing concerns the peptide ingredient or the finished nasal spray. Identity, chromatographic purity, and peptide content are separate analytical attributes and should not be inferred from one another.

Only tests explicitly documented for the relevant batch should be regarded as performed. Excipient information should be checked against the batch-specific CoA/SDS; neither the catalogue strength nor general peptide literature substitutes for formulation-specific documentation.

For research use only. Not for human or veterinary use. Not intended to diagnose, treat, cure, or prevent any disease. No dosing or administration directions are provided.